EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

ursodiol
ursocholic acid, deoxy-

Supplier Sponsors

Name:(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
CAS Number: 128-13-2Picture of molecule3D/inchi
Other(deleted CASRN):50809-41-1
ECHA EINECS - REACH Pre-Reg:204-879-3
FDA UNII: 724L30Y2QR
Nikkaji Web:J2.520H
Beilstein Number:3219888
MDL:MFCD00003680
XlogP3-AA:4.90 (est)
Molecular Weight:392.57960000
Formula:C24 H40 O4
BioActivity Summary:listing
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:cosmetic agents
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Melting Point: 203.00 °C. @ 760.00 mm Hg
Boiling Point: 547.10 °C. @ 760.00 mm Hg (est)
Flash Point: 570.00 °F. TCC ( 298.80 °C. ) (est)
logP (o/w): 3.000
Soluble in:
 water, 20 mg/L @ 20 °C (exp)
 water, 2.414 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
CosIng:cosmetic data
Cosmetic Uses: skin conditioning
skin protecting agents
 
Suppliers:
Alfa Biotechnology
For experimental / research use only.
Ursodeoxycholic acid 98%
BOC Sciences
For experimental / research use only.
Ursodeoxycholic Acid ≥99.0%
Odor: characteristic
Use: Ursodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone diss Gallstone-dissolving drugs; Anti-neoplastic; For the prevention and treatment of cholesterol gallstones; Reduces hyd
ExtraSynthese
For experimental / research use only.
Ursodeoxycholic Acid
Glentham Life Sciences
Ursodeoxycholic acid
Sigma-Aldrich: Sigma
For experimental / research use only.
Ursodeoxycholic acid ≥99%
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intraperitoneal-mouse LD50 1200 mg/kg
SKIN AND APPENDAGES (SKIN): HAIR: OTHER BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.

intravenous-mouse LD50 240 mg/kg
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.

oral-mouse LD50 > 10000 mg/kg
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.

intraperitoneal-rat LD50 700 mg/kg
Bollettino Chimico Farmaceutico. Vol. 126, Pg. 282, 1987.

intravenous-rat LD50 310 mg/kg
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.

oral-rat LD50 4600 mg/kg
Bollettino Chimico Farmaceutico. Vol. 126, Pg. 282, 1987.

Dermal Toxicity:
subcutaneous-mouse LD50 1000 mg/kg
"Modern Pharmaceuticals of Japan, IV," Tokyo, Japan Pharmaceutical, Medical and Dental Supply Exporters' Assoc., 1972Vol. -, Pg. 109, 1972.

subcutaneous-rat LD50 > 2000 mg/kg
Kiso to Rinsho. Clinical Report. Vol. 9, Pg. 3159, 1975.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
cosmetic agents
Recommendation for ursodiol usage levels up to:
 not for fragrance use.
 
Recommendation for ursodiol flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
ClinicalTrials.gov:search
Daily Med:search
Chemical Carcinogenesis Research Information System:Search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :31401
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:2
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
Chemidplus:0000128132
RTECS:FZ2000000 for cas# 128-13-2
 
References:
 (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):31401
Pubchem (sid):134974576
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):C07880
HMDB (The Human Metabolome Database):HMDB00946
FooDB:FDB022332
Export Tariff Code:2918.19.9000
VCF-Online:VCF Volatile Compounds in Food
ChemSpider:View
Wikipedia:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 found in nature
 
Synonyms:
 actigall
 arsacol
 cholit-ursan
 delursan
 destolit
 deursil
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
3-alpha,7-beta-dihydroxy-5-beta-cholanoic acid
3,7-dihydroxycholan-24-oic acid
3-alpha,7-beta-dihydroxycholanic acid
3-alpha,7-beta-dioxycholanic acid
7-beta-hydroxylithocholic acid
 litursol
 lyeton
17-beta-(1-methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
 peptarom
 solutrat
 urso 250
 urso DS
 urso forte
 ursobilin
 ursochol
 ursocholic acid, deoxy-
 ursodeoxycholic acid
 ursodesoxycholic acid
 ursofalk
 ursolvan
 

Articles:

PubMed:Variation of pathways and network profiles reveals the differential pharmacological mechanisms of each effective component to treat middle cerebral artery ischemia-reperfusion mice.
PubMed:Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog.
PubMed:Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.
PubMed:Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSC-3 Cells through the Caspases.
PubMed:Cholesterol lowering effect in the gall bladder of dogs by a standardized infusion of Herniaria hirsuta L.
PubMed:New therapies for primary biliary cirrhosis.
PubMed:The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases.
PubMed:Modulation of GSH with exogenous agents leads to changes in glyoxalase 1 enzyme activity in VL-17A cells exposed to chronic alcohol plus high glucose.
PubMed:Determination of bile acids by hollow fibre liquid-phase microextraction coupled with gas chromatography.
PubMed:Refeeding syndrome in a patient with advanced kidney failure due to nephronophthisis.
PubMed:[Rapid identification of two new isomers in bear bile powder by LC-Q-TOF-MS combined with PCC oxidation].
PubMed:Extraction of lycopene from tomato paste by ursodeoxycholic acid using the selective inclusion complex method.
PubMed:Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults.
PubMed:Primary biliary cirrhosis: therapeutic advances.
PubMed:[Modern approaches to the treatment of biliary pathology in young patients with obesity].
PubMed:Anti-oxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat.
PubMed:Ursodeoxycholic acid for primary biliary cirrhosis.
PubMed:Effects of Korean red ginseng as an adjuvant to bile acids in medical dissolution therapy for gallstones: a prospective, randomized, controlled, double-blind pilot trial.
PubMed:B cell depletion in treating primary biliary cirrhosis: pros and cons.
PubMed:Dietary polyamine intake and risk of colorectal adenomatous polyps.
PubMed:Ursodeoxycholic acid treatment in a rat model of cancer cachexia.
PubMed:Protective effect of Öküzgözü (Vitis vinifera L. cv.) grape juice against carbon tetrachloride induced oxidative stress in rats.
PubMed:Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
PubMed:Linking endoplasmic reticulum stress to cell death in hepatocytes: roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death.
PubMed:Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies.
PubMed:[Non-alcoholic fatty liver disease and cardiovascular risk].
PubMed:Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence.
PubMed:Hepatoprotective bile acid 'ursodeoxycholic acid (UDCA)' Property and difference as bile acids.
PubMed:Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria.
PubMed:Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
PubMed:[Pharmacological capacities of the prevention of colorectal cancer].
PubMed:Hepatic branch vagotomy can block liver regeneration enhanced by ursodesoxycholic acid in 66% hepatectomized rats.
PubMed:Postprandial changes in serum unconjugated bile acid concentrations in healthy beagles.
PubMed:[Influence of ursodeoxycholic acid on the therapeutic effects of low-calorie diet in obesity and hyperlipidemia rats with steatohepatitis].
PubMed:Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients.
PubMed:Stability of oral suspensions of ursodiol made from tablets.
PubMed:Chemoprevention of colorectal cancer.
PubMed:[3 beta-Hydroxysteroid-delta 5-oxidoreductase/isomerase deficiency].
PubMed:Apolipoprotein E polymorphism in alagille syndrome and progressive familial intrahepatic cholestasis.
PubMed:Modulation of colonic xenobiotic metabolizing enzymes by feeding bile acids: comparative effects of cholic, deoxycholic, lithocholic and ursodeoxycholic acids.
PubMed:Studies on N-nitroso bile acid amides in relation to their possible role in gastrointestinal cancer.
PubMed:The indirect UV detection in the analysis of ursodeoxycholic acid and related compounds by HPCE.
PubMed:Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation.
PubMed:Advances in parenteral nutrition.
PubMed:Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.
PubMed:Functional dyspepsia: how could a biliary dyspepsia sub-group be recognized? A methodological approach.
PubMed:Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: response to ursodeoxycholic acid treatment.
PubMed:Chemo- and dietary prevention of colorectal cancer.
PubMed:Effects of different formula feeds on the developmental pattern of urinary bile acid excretion in infants.
PubMed:Gallstone lithotripsy.
PubMed:Effects of massive small bowel resection on metabolism of bile acids and vitamin D3 and gastrin release in dogs.
PubMed:Increased gallbladder residual volume in nonresponders to extracorporeal shock wave lithotripsy of gallbladder stones.
PubMed:Lack of benefit of ursodeoxycholic acid in drug-induced cholestasis in the rat.
PubMed:Feeding diets containing 2% cheno- or urso-deoxycholic acid or cholestyramine to rats for two weeks alters intestinal morphology and bile acid absorption.
PubMed:Medical management of gallstones: a cost-effectiveness analysis.
PubMed:Effect of ursodeoxycholic acid (UDCA) on pancreatic enzyme secretion and gallbladder emptying.
PubMed:Effect of aging and dietary restriction on bile acid metabolism in rats.
PubMed:Extracorporeal shock-wave lithotripsy of gallstones: Boston experience with the Dornier MPL 9000 lithotripter.
PubMed:Ursodiol: a cholesterol gallstone solubilizing agent.
PubMed:In vitro transformation of cheno- and ursodeoxycholic acids and their 7-oleyl esters by human intestinal microflora.
PubMed:Transformation of sulfated bile acids by human intestinal microflora.
PubMed:Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids.
PubMed:Serum bile acids in Gilbert's syndrome after oral load of chenodeoxycholic acid.
PubMed:Epimerization of the four 3,7-dihydroxy bile acid epimers by human fecal microorganisms in anaerobic mixed cultures and in feces.
PubMed:A treatment of non-ketotic hyperglycinaemia.
PubMed:Dissolution of cholesterol gallstones by bile acids in hamsters.
PubMed:Effect of cecum and appendix on 7 alpha-dehydroxylation and 7 beta-epimerization of chenodeoxycholic acid in the rabbit.
PubMed:Cholesterol gallstone formation and prevention by chenodeoxycholic and ursodeoxycholic acids. A new hamster model.
 
Notes:
an epimer of chenodeoxycholic acid. it is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. its administration changes the composition of bile and may dissolve gallstones. it is used as a cholagogue and choleretic. An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. [HMDB]
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy